loading
Schlusskurs vom Vortag:
$26.74
Offen:
$26.98
24-Stunden-Volumen:
862.28K
Relative Volume:
0.20
Marktkapitalisierung:
$20.13B
Einnahmen:
$956.00K
Nettoeinkommen (Verlust:
$-221.32M
KGV:
-84.72
EPS:
-0.32
Netto-Cashflow:
$-142.25M
1W Leistung:
-3.25%
1M Leistung:
+27.35%
6M Leistung:
+21.20%
1J Leistung:
+153.51%
1-Tages-Spanne:
Value
$26.78
$27.69
1-Wochen-Bereich:
Value
$26.50
$29.07
52-Wochen-Spanne:
Value
$8.88
$36.91

Summit Therapeutics Inc Stock (SMMT) Company Profile

Name
Firmenname
Summit Therapeutics Inc
Name
Telefon
305-203-2034
Name
Adresse
601 BRICKELL KEY DRIVE, MIAMI
Name
Mitarbeiter
159
Name
Twitter
@summitplc
Name
Nächster Verdiensttermin
2025-02-24
Name
Neueste SEC-Einreichungen
Name
SMMT's Discussions on Twitter

Vergleichen Sie SMMT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SMMT
Summit Therapeutics Inc
27.10 20.39B 956.00K -221.32M -142.25M -0.32
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.79 118.34B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
559.93 60.31B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
344.41 42.35B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
604.34 36.43B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
301.43 31.87B 3.81B -644.79M -669.77M -6.24

Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-01 Eingeleitet UBS Buy
2025-06-11 Eingeleitet Leerink Partners Underperform
2025-03-26 Hochstufung Citigroup Neutral → Buy
2025-03-21 Eingeleitet Cantor Fitzgerald Overweight
2025-03-12 Eingeleitet Evercore ISI Outperform
2025-02-28 Eingeleitet Goldman Buy
2025-01-08 Eingeleitet Truist Buy
2024-12-11 Eingeleitet Wells Fargo Overweight
2024-12-06 Eingeleitet Jefferies Buy
2024-11-04 Eingeleitet JMP Securities Mkt Outperform
2024-09-27 Herabstufung Citigroup Buy → Neutral
2024-08-12 Eingeleitet H.C. Wainwright Buy
2024-05-07 Eingeleitet Citigroup Buy
2024-03-26 Eingeleitet Stifel Buy
2018-06-28 Herabstufung Janney Buy → Neutral
2018-05-02 Eingeleitet Janney Buy
2018-04-12 Bestätigt Needham Buy
2018-02-13 Eingeleitet BTIG Research Buy
2018-01-04 Eingeleitet SunTrust Buy
2017-12-01 Fortgesetzt H.C. Wainwright Buy
2016-11-16 Bestätigt RBC Capital Mkts Outperform
2016-10-05 Bestätigt Needham Buy
2016-09-16 Eingeleitet H.C. Wainwright Buy
2015-03-30 Eingeleitet Needham Buy
2015-03-30 Eingeleitet Oppenheimer Outperform
Alle ansehen

Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten

pulisher
05:36 AM

How high can Summit Therapeutics Inc. stock goProfit Target Planning with Exit Confidence - Newser

05:36 AM
pulisher
02:17 AM

Summit Therapeutics Inc. recovery potential after sell offConsistent Return Setup with Exit Strategy - Newser

02:17 AM
pulisher
Jul 29, 2025

Is Summit Therapeutics Inc. Stock a Good Fit for Conservative InvestorsSmart Trade Mapping with Entry Details - Newser

Jul 29, 2025
pulisher
Jul 29, 2025

Is Summit Therapeutics Inc. stock a growth or value playFree Day Trading Signals With High Precision - Newser

Jul 29, 2025
pulisher
Jul 28, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Summit Therapeutics Inc. (SMMT) And Encourages Shareholders to Connect - ACCESS Newswire

Jul 28, 2025
pulisher
Jul 28, 2025

Summit Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada

Jul 28, 2025
pulisher
Jul 28, 2025

Is Summit Therapeutics Inc. stock poised for growthTechnical Setup Guide for Daily Watchlist - Newser

Jul 28, 2025
pulisher
Jul 28, 2025

Why is Summit Therapeutics Inc. stock attracting strong analyst attentionRapid-fire capital growth - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Summit Therapeutics Joins Elite Club Of Stocks With RS Ratings Over 90 - Investor's Business Daily

Jul 28, 2025
pulisher
Jul 28, 2025

Ivonescimab's Dual-Action Revolution: A Catalyst for Akeso and Summit Therapeutics in the $500M+ Lung Cancer Market - AInvest

Jul 28, 2025
pulisher
Jul 27, 2025

Does Summit Therapeutics Inc. stock perform well during market downturnsBuild a portfolio that withstands market volatility - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - MarketScreener

Jul 27, 2025
pulisher
Jul 27, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - PR Newswire

Jul 27, 2025
pulisher
Jul 27, 2025

Is Summit Therapeutics Inc. Stock Overbought or Oversold RSI Indicator AnalysisVolume Spike Monitors - Newser

Jul 27, 2025
pulisher
Jul 27, 2025

When is Summit Therapeutics Inc. stock expected to show significant growthAchieve consistent profits with proven strategies - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 25, 2025

Summit Therapeutics Jumps 4% As Technicals Signal Bullish Breakout Potential - AInvest

Jul 25, 2025
pulisher
Jul 25, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Summit Therapeutics Inc. (SMMT) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Jul 25, 2025
pulisher
Jul 25, 2025

Summit Therapeutics Soars 4.64%—Could This Biotech Breakthrough Signal a Game-Changer? - AInvest

Jul 25, 2025
pulisher
Jul 24, 2025

What drives Summit Therapeutics Inc. stock priceConsistent double returns - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Summit Therapeutics Inc. (SMMT) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Jul 24, 2025
pulisher
Jul 24, 2025

Bank of New York Mellon Corp Has $6.57 Million Stock Holdings in Summit Therapeutics PLC (NASDAQ:SMMT) - Defense World

Jul 24, 2025
pulisher
Jul 24, 2025

Will Summit Therapeutics Inc. stock benefit from AI tech trendsTriple-digit growth rates - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings - MSN

Jul 24, 2025
pulisher
Jul 24, 2025

Summit Therapeutics PLC (NASDAQ:SMMT) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Jul 24, 2025
pulisher
Jul 23, 2025

Is Summit Therapeutics Inc. a good long term investmentHigh-octane financial growth - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Summit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Jul 23, 2025
pulisher
Jul 23, 2025

Meet the Biotech Stock That Rocketed 775% Higher - AOL.com

Jul 23, 2025
pulisher
Jul 22, 2025

What analysts say about Summit Therapeutics Inc. stockExplosive capital appreciation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Summit Therapeutics Inc. (SMMT) And Encourages Investors to Connect - ACCESS Newswire

Jul 22, 2025
pulisher
Jul 22, 2025

3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results - The Motley Fool

Jul 22, 2025
pulisher
Jul 22, 2025

Summit Therapeutics Inc. Stock Analysis and ForecastDouble-digit growth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Summit Therapeutics Inc. (SMMT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Jul 21, 2025
pulisher
Jul 21, 2025

This Healthcare Stock's Revolutionary Drug Could Make Early Investors Rich - Yahoo Finance

Jul 21, 2025
pulisher
Jul 21, 2025

3 Monster Stocks in the Making to Buy Right Now - The Globe and Mail

Jul 21, 2025
pulisher
Jul 20, 2025

Trading (SMMT) With Integrated Risk Controls - news.stocktradersdaily.com

Jul 20, 2025
pulisher
Jul 20, 2025

Summit Therapeutics PLC (NASDAQ:SMMT) Shares Acquired by Cerity Partners LLC - Defense World

Jul 20, 2025
pulisher
Jul 19, 2025

Published on: 2025-07-19 02:49:19 - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Summit Therapeutics Inc. (SMMT) And Encourages Investors to Reach Out - ACCESS Newswire

Jul 18, 2025

Finanzdaten der Summit Therapeutics Inc-Aktie (SMMT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Summit Therapeutics Inc-Aktie (SMMT) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
DUGGAN ROBERT W
Co-Chief Executive Officer
May 30 '25
Option Exercise
2.64
74,545
196,799
555,754,696
$107.25
price up icon 2.26%
$37.37
price up icon 0.19%
$77.95
price up icon 0.71%
$111.50
price up icon 0.02%
biotechnology ONC
$301.74
price down icon 1.12%
Kapitalisierung:     |  Volumen (24h):